AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study

Reuters03-20

AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study

Aptar said its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of investigational INNA-051 nasal spray.
The study is evaluating safety and tolerability in adults at increased risk of exposure to viral respiratory infections.
Aptar CSP Technologies’ container closure system with 3-Phase Activ-Polymer technology will be used to help protect the powder formulation against moisture.
Alex Theodorakis, President of Aptar Pharma Prescription, said Aptar is supporting ENA Respiratory’s clinical development work through the UDS powder nasal delivery system.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260319657698) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620715172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 05:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620715172","market":"nz","top_or_hot":-1,"title":"AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/ATR\">Aptar</a> said its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of investigational INNA-051 nasal spray.\n        </li>\n<li>\n          The study is evaluating safety and tolerability in adults at increased risk of exposure to viral respiratory infections.\n        </li>\n<li>\n          Aptar CSP Technologies’ container closure system with 3-Phase Activ-Polymer technology will be used to help protect the powder formulation against moisture.\n        </li>\n<li>\n          Alex Theodorakis, President of Aptar Pharma Prescription, said Aptar is supporting ENA Respiratory’s clinical development work through the UDS powder nasal delivery system.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260319657698) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 05:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          <a href=\"https://laohu8.com/S/ATR\">Aptar</a> said its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of investigational INNA-051 nasal spray.\n        </li>\n<li>\n          The study is evaluating safety and tolerability in adults at increased risk of exposure to viral respiratory infections.\n        </li>\n<li>\n          Aptar CSP Technologies’ container closure system with 3-Phase Activ-Polymer technology will be used to help protect the powder formulation against moisture.\n        </li>\n<li>\n          Alex Theodorakis, President of Aptar Pharma Prescription, said Aptar is supporting ENA Respiratory’s clinical development work through the UDS powder nasal delivery system.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260319657698) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATR","symbol_name":"Aptar","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1f4wm0:1","article_id":"2620715172","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620715172","pubTimestamp":1773954036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptar said its Unidose  Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of investigational INNA-051 nasal spray.The study is evaluating safety and tolerability in adults at increased risk of exposure to viral respiratory infections.Aptar CSP Technologies’ container closure system with 3-Phase Activ-Polymer technology will be used to help protect the powder formulation against moisture.Alex Theodorakis, President of Aptar Pharma Prescription, said Aptar is supporting ENA Respiratory’s clinical development work through the UDS powder nasal delivery system.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATR":"Aptar","BK4126":"金属与玻璃容器"},"translate_title":"AptarGroup与ENA Respiratory合作，为INNA-051 II期研究提供单剂量粉末鼻喷雾系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATR":0.9},"content_text":"AptarGroup partners with ENA Respiratory to supply Unidose powder nasal spray system for INNA-051 Phase II study\n    \n\n\nAptar said its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory’s Phase II clinical study of investigational INNA-051 nasal spray.\n        \n\n          The study is evaluating safety and tolerability in adults at increased risk of exposure to viral respiratory infections.\n        \n\n          Aptar CSP Technologies’ container closure system with 3-Phase Activ-Polymer technology will be used to help protect the powder formulation against moisture.\n        \n\n          Alex Theodorakis, President of Aptar Pharma Prescription, said Aptar is supporting ENA Respiratory’s clinical development work through the UDS powder nasal delivery system.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260319657698) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620715172","isCrawlerRequest":true}